NL-OMON50931
Recruiting
Phase 4
Monitoring the effect of oral anticoagulants during cardiac catheterisation - POPular MEASURE trial
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- coronary artery disease
- Sponsor
- Sint Antonius Ziekenhuis
- Enrollment
- 120
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient must meet all of the following criteria:
- •\- Male or female \>\= 18 years
- •\- Undergoing non\-emergent CAG or PCI
- •\- Loaded with P2Y12 inhibitors before PCI
- •\- Patients with signed informed consent
Exclusion Criteria
- •Patients who fulfill the above mentioned inclusion criteria but who manifest
- •any of the following exclusion criteria will not be eligible for the study: \-
- •Patients with hematologic, renal (estimated glomerular filtration \<30
- •ml/min/1\.73m2\), hepatic (liver enzymes \>2 times the upper limit of normal),
- •inflammatory (CRP \>2 times the upper limit of normal) or neoplastic disorders \-
- •Patients using nonsteroidal anti\-inflammatory drugs, corticosteroids, or
- •hormone replacement therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Monitoring the effect of blood thinners during percutaneous coronary interventioAnticoagulation during percutaneous coronary interventionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-005298-29-NLSt. Antonius Hospital120
Recruiting
Not Applicable
Effects of treatment with oral anticoagulant associated with antibiotic therapy in Covid-19Covid-19B04.820.578.500.540.150RBR-7nzwkpgniversidade do Sul de Santa Catarina
Not yet recruiting
Not Applicable
ew Oral Anticoagulants (NOAC) Study: Investigation of laboratory tests an development of a gold standard test for monitoring dabigatran and rivaroxaban therapyblood clotthrombosis1000752110014523NL-OMON39575Catharina-ziekenhuis120
Active, not recruiting
Phase 1
A study to demonstrate that a new antikoagulation therapy with apixaban is safe compared to another antikoagulation therapy with phenprocoumon in patients with chronic kidney disease and atrial fibrillation.End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment and Atrial FibrillationMedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 23.1Level: LLTClassification code 10076412Term: Chronic kidney disease stage 5System Organ Class: 100000004857Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-005503-84-DEKompetenznetz Vorhofflimmern e.V.108
Recruiting
Phase 2
Comparison of the effects of Rivaroxaban and Apixaban with Heparin and Enoxaparin in patients undergoing gynecological oncological surgery.IRCT20220211053991N1Iran University of Medical Sciences80